UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 8-K


                             CURRENT REPORT PURSUANT
                          TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

     Date of report (Date of earliest event reported):  OCTOBER 14, 2004   
                                                        ------------------------

                               ENZO BIOCHEM, INC.
--------------------------------------------------------------------------------
             (Exact Name of Registrant as Specified in Its Charter)

                                    NEW YORK
--------------------------------------------------------------------------------
                 (State or Other Jurisdiction of Incorporation)

                         001-09974                       13-2866202
--------------------------------------------------------------------------------
                 (Commission File Number)      (IRS Employer Identification No.)

                  60 EXECUTIVE BOULEVARD
                   FARMINGDALE, NEW YORK                    11735
         (Address of Principal Executive Offices)        (Zip Code)
--------------------------------------------------------------------------------

                                 (631-755-5500)
--------------------------------------------------------------------------------
              (Registrant's Telephone Number, Including Area Code)


--------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)

     Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (SEE General Instruction A.2. below):

     |_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)

     |_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)

     |_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))

     |_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))





ITEM 2.02.       RESULTS OF OPERATONS AND FINANCIAL CONDITION.

On October 14,  2004,  the  Registrant  issued a press  release  announcing  its
operating results for the quarter and fiscal year ended July 31, 2004. A copy of
the press release is furnished as Exhibit 99.1 to this Current Report.

The information in this Current Report and the exhibit attached hereto are being
"furnished"  hereunder  and shall not be deemed filed for purposes of Section 18
of the  Securities  Exchange Act of 1934, as amended (the "Exchange  Act"),  nor
shall they be deemed  incorporated  by  reference  into any filings  made by the
Registrant with the Securities and Exchange Commission under the Exchange Act or
the Securities  Act of 1933, as amended,  except as shall be expressly set forth
by specific reference in such filings.





                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.


                                     ENZO BIOCHEM, INC.


Date:  October 14, 2004              By:   /s/ Barry Weiner
                                           --------------------------------
                                           Barry Weiner
                                           President and Chief Financial Officer





                                  EXHIBIT INDEX



Exhibit No.         Description
-----------         -----------
99.1                Press Release of Enzo Biochem, Inc., dated October 14, 2004.